Obesity Drug Safety
- All
- News
-
The Lancet Reports A Boom In Counterfeit Obesity Drugs: What You Need To Know
A new Lancet report pinpoints that a boom in counterfeit obesity drugs is taking place. Here is what you need to know about the dangers that these drugs pose and why following the properly established medical guidance is key to being safe.
-
India Cracks Down On Ads For Weight-Loss Drugs Like GLP-1 In New Advisory
India's Health Ministry has warned pharmaceutical firms against promoting GLP-1 weight-loss drugs to the public. The CDSCO says direct or indirect advertising, including influencer campaigns, violates drug laws and could attract regulatory action.
-
Stopping Weight-Loss Injections May Trigger Rapid Weight Regain: Oxford Study
A growing body of research shows that people who stop GLP-1 weight-loss injections such as Ozempic and Mounjaro often regain a significant portion of the weight within a year.
-
Novo Nordisk Sues Telehealth Company Over 'Knock-Off' Weight Loss Drugs, Flags Patient Safety Risks
The lawsuit, filed in the US, alleges that Hims infringed Novo Nordisk's patent by mass marketing compounded semaglutide products that have not been cleared by the US Food and Drug Administration (FDA).
-
Ensure Weight Loss Drugs Are Safe, Legal Before Use In 2026: UK Health Agency
New Year is the time for many people to pledge reforms in habits and lifestyle, something resorting to drastic measures, but UK's Medicines and Healthcare products Regulatory Agency (MHRA) has urged the people to make sure an
-
Popular Weight-Loss Drugs Like Wegovy Fail To Lower Obesity-Related Cancer Risks, Study Finds
Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type 2 diabetes, overweight, or obesity. These studies involved a total of more than 94,000 participants.
-
Some Diabetes Patients Achieve Remission With GLP-1 Drugs: Italian Study
An Italian study shows that using GLP-1 receptor agonists can lead to remission in up to 18% of cases, especially when used early and in patients with fewer complications.
-
WHO Adds Key Diabetes, Weight-Loss Drugs To Essential Medicines List
The World Health Organization has added key GLP-1 drugs, semaglutide and tirzepatide, to its Essential Medicines List for type 2 diabetes with obesity or comorbidities.
-
WHO Backs Weight-Loss Drugs To Treat Diabetes, Obesity, Urges Cheap Generics
The World Health Organization recommended a range of blockbuster weight-loss drugs to treat diabetes and obesity globally for the first time on Friday, calling for cheap generic versions to be made available for people in developing countries.
-
Obesity-Made Fatty Liver Drives Midcap Race For Wonder Drug
The race is on to identify the wonder drug that will treat an increasingly common consequence of obesity: The fatty liver disease known as nonalcoholic steatohepatitis, or NASH.
-
The Lancet Reports A Boom In Counterfeit Obesity Drugs: What You Need To Know
A new Lancet report pinpoints that a boom in counterfeit obesity drugs is taking place. Here is what you need to know about the dangers that these drugs pose and why following the properly established medical guidance is key to being safe.
-
India Cracks Down On Ads For Weight-Loss Drugs Like GLP-1 In New Advisory
India's Health Ministry has warned pharmaceutical firms against promoting GLP-1 weight-loss drugs to the public. The CDSCO says direct or indirect advertising, including influencer campaigns, violates drug laws and could attract regulatory action.
-
Stopping Weight-Loss Injections May Trigger Rapid Weight Regain: Oxford Study
A growing body of research shows that people who stop GLP-1 weight-loss injections such as Ozempic and Mounjaro often regain a significant portion of the weight within a year.
-
Novo Nordisk Sues Telehealth Company Over 'Knock-Off' Weight Loss Drugs, Flags Patient Safety Risks
The lawsuit, filed in the US, alleges that Hims infringed Novo Nordisk's patent by mass marketing compounded semaglutide products that have not been cleared by the US Food and Drug Administration (FDA).
-
Ensure Weight Loss Drugs Are Safe, Legal Before Use In 2026: UK Health Agency
New Year is the time for many people to pledge reforms in habits and lifestyle, something resorting to drastic measures, but UK's Medicines and Healthcare products Regulatory Agency (MHRA) has urged the people to make sure an
-
Popular Weight-Loss Drugs Like Wegovy Fail To Lower Obesity-Related Cancer Risks, Study Finds
Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type 2 diabetes, overweight, or obesity. These studies involved a total of more than 94,000 participants.
-
Some Diabetes Patients Achieve Remission With GLP-1 Drugs: Italian Study
An Italian study shows that using GLP-1 receptor agonists can lead to remission in up to 18% of cases, especially when used early and in patients with fewer complications.
-
WHO Adds Key Diabetes, Weight-Loss Drugs To Essential Medicines List
The World Health Organization has added key GLP-1 drugs, semaglutide and tirzepatide, to its Essential Medicines List for type 2 diabetes with obesity or comorbidities.
-
WHO Backs Weight-Loss Drugs To Treat Diabetes, Obesity, Urges Cheap Generics
The World Health Organization recommended a range of blockbuster weight-loss drugs to treat diabetes and obesity globally for the first time on Friday, calling for cheap generic versions to be made available for people in developing countries.
-
Obesity-Made Fatty Liver Drives Midcap Race For Wonder Drug
The race is on to identify the wonder drug that will treat an increasingly common consequence of obesity: The fatty liver disease known as nonalcoholic steatohepatitis, or NASH.
